Search results for: Precision Medicine
Filter search results
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
Report does not recommend price transparency for on-patent medicines, but buyers should share multi-source product price data among themselves. Transparency of the procurement process encourages bidders. In many cases, referencing…
OHE at the 2019 International Health Economics Association (iHEA) World Congress
5 July 2019
…issues concerning the quality of care, variation of hospital readmission, waiting time for hospital admission etc. Quantifying the Life-Cycle Value of Innovative Medicines: The Case of Risperidone and Second-Generation Antipsychotics…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…target patient populations of both orphan and non-orphan drugs from the Scottish Medicines Consortium (SMC) and National Institute for Health and Care Excellence (NICE). Both differences in research and development…
OHE Annual Lecture 2026 | Paying for prevention: the global health financing challenge
6 October 2026, 6:00pm
…as well as writing a weekly column in the Business Mirror newspaper and serving as faculty at University of the Philippines College of Medicine, the Ateneo de Manila University Graduate School of…
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
…TVF criteria. Source: WG MoCA-OMP Transparent Value Framework.pdf (org.s3.amazonaws.com) OHE supported Vifor Pharma in a pilot for their medicine avacopan in ANCA-associated vasculitis (AAV). This involved three meetings with payer…
US Healthcare Reform: Monumental Health System Transformation or Fatally Flawed Compromise?
1 September 2010
…at the School of Medicine. His remarks focused on the national health care… The speaker for the OHE’s 17th Annual Lecture was Dr Alan Garber, Director both of Stanford University’s…
The Impact of Health Technology Assessment on Drug Development
3 January 2009
…apply to all new prescription medicines; in others, HTA is required of industry… Health technology assessment (HTA) has become a critical basis for pricing and reimbursement decision-making worldwide. In some…
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
4 January 2019
…data across (and potentially within) countries and cultures. Failure to recognise and account for these differences could lead to incorrect conclusions about the effectiveness and cost effectiveness of new medicines…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
1 June 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies….